Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCS002
- Development stage
- Preclinical
- Lead developer
- Glen Clova Scientific
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
GCS002 is a preclinical biologic drug candidate being developed for the treatment of atopic dermatitis. It is part of Glen Clova Scientific’s pipeline, which leverages virus-like particle (VLP) technology to create active biologic drugs targeting chronic inflammatory and autoimmune disorders. The VLP-based approach aims to modulate immune responses, with GCS002 specifically focused on interleukin-13 (IL-13), a cytokine implicated in the pathogenesis of atopic dermatitis[2][3][9]. The drug is currently in preclinical development.
02
Targets
IL-13 (Interleukin-13)
Beyond the preview
Go deeper on GCS002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCS002.